Arcadia Biosciences Reports Q4 Operating Expenses of $2.276 Million

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: Mar 26 2026

0mins

RKDA-0.71%

Should l Buy RKDA?

Source: moomoo

Operating Expenses: The operating expenses for Arcadia Biosciences in the fourth quarter amounted to USD 2.276 million.
Financial Overview: The report highlights the financial performance and expenditures of the company during the specified quarter.
Company Focus: Arcadia Biosciences is engaged in biotechnology, focusing on developing innovative agricultural solutions.
Future Outlook: The financial results may influence future investments and strategic decisions for the company moving forward.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RKDA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on RKDA

About RKDA

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Arcadia Biosciences Reports Q4 Financial Results

Mar 26 2026seekingalpha

Disappointing Financial Results: Arcadia Biosciences reported a Q4 GAAP EPS of -$0.97, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
Significant Revenue Decline: The company’s Q4 revenue was $0.9 million, down 26.2% year-over-year, a trend that may undermine investor confidence in the company’s future growth potential, particularly in the competitive biotech sector.
Negative Market Reaction: The earnings report, which fell short of market expectations, could lead investors to adopt a cautious stance regarding the company’s future financial performance, potentially putting pressure on the stock price and affecting its ability to raise capital and pursue strategic investments.
Need for Strategic Reevaluation: In light of the ongoing revenue decline, Arcadia Biosciences may need to reassess its business model and market strategies to achieve sustainable growth in the future and restore investor confidence.